Yasaka M, Oomura M, Ikeno K, Naritomi H, Minematsu K
Cerebrovascular Division, Department of Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan.
Ann Hematol. 2003 Feb;82(2):121-3. doi: 10.1007/s00277-002-0568-y. Epub 2002 Nov 29.
We investigated the effect of prothrombin complex concentrate (PCC) on the international normalized ratio (INR) and blood coagulation system in two emergent patients treated with warfarin for secondary prevention of cardioembolic stroke due to nonvalvular atrial fibrillation. An 80-year-old woman developed massive subcutaneous hemorrhage and swelling on her right upper extremity with weak pulsation of the right radial artery and had an INR above 10. An 83-year-old man had pleural effusion with an INR value of 6.69 and pleural puncture was immediately required. We administered 500 IU of PCC to the two patients (17.2 IU/kg and 12.5 IU/kg) with 10 mg of vitamin K. The INR decreased to 1.12 and 1.85, respectively, with an increase of plasma levels of protein C and coagulant factors IIa, VIIa, IXa, and Xa 10 min after administration. The plasma levels of the thrombin-antithrombin III complex increased (from 4.0 to 12.0 micro g/l and from 0.5 to 28.9 micro g/l, respectively, normal value <3.0), but prothrombin fragment 1+2 increased minimally 10 min after administration (from 0.4 to 1.1 nmol/ml and from 0.4 to 0.7 nmol/ml, respectively, normal value 0.4-1.4 nmol/ml). Plasma levels of D-dimer remained unchanged. The massive subcutaneous hemorrhage in the former patient improved in 14 days. Anticoagulation was restarted in the latter patient after 14 days of PCC administration. There were no embolic episodes during the month after PCC administration. In conclusion, a small amount of PCC may be effective in immediately correcting increased INR levels with increased plasma levels of protein C and coagulant factors IIa, VIIa, IXa, and Xa and may partially activate the coagulation system without any effects on plasma levels of D-dimer.
我们研究了凝血酶原复合物浓缩剂(PCC)对两名因非瓣膜性心房颤动接受华法林二级预防心源性栓塞性卒中的急诊患者的国际标准化比值(INR)和凝血系统的影响。一名80岁女性右上肢出现大量皮下出血和肿胀,右桡动脉搏动微弱,INR高于10。一名83岁男性有胸腔积液,INR值为6.69,需要立即进行胸腔穿刺。我们给这两名患者分别静脉注射500IU的PCC(分别为17.2IU/kg和12.5IU/kg)并同时给予10mg维生素K。给药10分钟后,INR分别降至1.12和1.85,血浆蛋白C和凝血因子IIa、VIIa、IXa及Xa水平升高。凝血酶 - 抗凝血酶III复合物的血浆水平升高(分别从4.0升至12.0μg/L和从0.5升至28.9μg/L,正常值<3.0),但给药10分钟后凝血酶原片段1 + 2升高幅度极小(分别从0.4升至1.1nmol/ml和从0.4升至0.7nmol/ml,正常值0.4 - 1.4nmol/ml)。D - 二聚体的血浆水平保持不变。前一名患者的大量皮下出血在14天内得到改善。后一名患者在给予PCC 14天后重新开始抗凝治疗。在给予PCC后的一个月内未发生栓塞事件。总之,少量PCC可能有效迅速纠正升高的INR水平,同时提高血浆蛋白C和凝血因子IIa、VIIa、IXa及Xa水平,并且可能部分激活凝血系统,而对D - 二聚体的血浆水平无任何影响。